Iron Deficiency Anemia Clinical Trial
Official title:
Iron and Vaccine-preventable Viral Disease
NCT number | NCT04915820 |
Other study ID # | DIVA II |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 29, 2021 |
Est. completion date | September 9, 2021 |
Verified date | September 2021 |
Source | Jomo Kenyatta University of Agriculture and Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Vaccines often underperform in Africa compared to high-income countries. Why vaccines do not work as well in Africa remains uncertain. Malnutrition likely plays a role. Our study objective is to assess whether iron deficiency anaemia in young women impairs their immune response to the COVID-19 vaccine, and whether iron treatment improves their response.
Status | Completed |
Enrollment | 121 |
Est. completion date | September 9, 2021 |
Est. primary completion date | September 9, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 18-55 years old Zinc protoporphyrin > or equal 40 mmol/mol heme hemoglobin < or equal 109 g/L no malaria no known HIV infection no medical condition that precludes study involvement no iron supplementation 1 week prior to study start no recent tuberculosis infection no vaccination of yellow fever or influenza prior to enrolment not pregnant Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
Kenya | Msambweni County Referral Hospital | Msambweni | Kwale |
Lead Sponsor | Collaborator |
---|---|
Jomo Kenyatta University of Agriculture and Technology |
Kenya,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Antibody titers | day 35 | ||
Primary | Antibody titers | day 63 | ||
Primary | Seroconversion | day 35 | ||
Primary | Seroconversion | day 63 | ||
Primary | Antibody avidity index | percentage of antibodies that remain bound to beads | day 35 | |
Primary | Antibody avidity index | percentage of antibodies that remain bound to beads | day 63 | |
Secondary | antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response | immunoassay | day 0 | |
Secondary | antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response | immunoassay | day 7 | |
Secondary | antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response | immunoassay | day 35 | |
Secondary | antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response antiviral immunoglobulin G response | immunoassay | day 63 | |
Secondary | immune cell populations | number and type of immune cells | day 0 | |
Secondary | immune cell populations | number and type of immune cells | day 7 | |
Secondary | immune cell populations | number and type of immune cells | day 35 | |
Secondary | immune cell populations | number and type of immune cells | day63 | |
Secondary | Proteomics | Proteins involved in immune response | day 0 | |
Secondary | Proteomics | Proteins involved in immune response | day 7 | |
Secondary | Proteomics | Proteins involved in immune response | day 35 | |
Secondary | Proteomics | Proteins involved in immune response | day 63 | |
Secondary | Transcriptomics | Genes involved in immune response | day 0 | |
Secondary | Transcriptomics | Genes involved in immune response | day 7 | |
Secondary | Transcriptomics | Genes involved in immune response | day 35 | |
Secondary | Transcriptomics | Genes involved in immune response | day 63 | |
Secondary | Immune cell cytokine secretion | ELISpot | day 7 | |
Secondary | Immune cell cytokine secretion | ELISpot | day 35 | |
Secondary | Hemoglobin | iron status parameter | day 0 | |
Secondary | Hemoglobin | iron status parameter | day 7 | |
Secondary | Hemoglobin | iron status parameter | day 35 | |
Secondary | Hemoglobin | iron status parameter | day 63 | |
Secondary | Plasma ferritin | iron status parameter | day 0 | |
Secondary | Plasma ferritin | iron status parameter | day 7 | |
Secondary | Plasma ferritin | iron status parameter | day 35 | |
Secondary | Plasma ferritin | iron status parameter | day 63 | |
Secondary | Transferrin receptor | iron status parameter | day 0 | |
Secondary | Transferrin receptor | iron status parameter | day 7 | |
Secondary | Transferrin receptor | iron status parameter | day 35 | |
Secondary | Transferrin receptor | iron status parameter | day 63 | |
Secondary | Transferrin saturation | iron status parameter | day 0 | |
Secondary | Transferrin saturation | iron status parameter | day 7 | |
Secondary | Transferrin saturation | iron status parameter | day 35 | |
Secondary | Transferrin saturation | iron status parameter | day 63 | |
Secondary | C-reactive protein | inflammation status parameter | day 0 | |
Secondary | C-reactive protein | inflammation status parameter | day 7 | |
Secondary | C-reactive protein | inflammation status parameter | day 35 | |
Secondary | C-reactive protein | inflammation status parameter | day 63 | |
Secondary | Alpha-glycoprotein | inflammation status parameter | day 0 | |
Secondary | Alpha-glycoprotein | inflammation status parameter | day 7 | |
Secondary | Alpha-glycoprotein | inflammation status parameter | day 35 | |
Secondary | Alpha-glycoprotein | inflammation status parameter | day 63 | |
Secondary | retinol binding protein | vitamin A status marker | day 0 | |
Secondary | retinol binding protein | vitamin A status marker | day 7 | |
Secondary | retinol binding protein | vitamin A status marker | day 35 | |
Secondary | retinol binding protein | vitamin A status marker | day 63 | |
Secondary | plasma zinc | day 35 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06027801 -
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
|
N/A | |
Completed |
NCT02282553 -
Gastric Capsule Examination for Iron Deficiency Anaemia
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT04913649 -
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
|
Phase 4 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Completed |
NCT01307007 -
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
|
Phase 2 | |
Completed |
NCT00982007 -
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
|
Phase 3 | |
Completed |
NCT00198848 -
Iron Supplementation Among Adolescent Girls in India
|
N/A | |
Completed |
NCT01166451 -
The Anemia Control Program: High or Low Iron Supplementation
|
N/A | |
Recruiting |
NCT03893045 -
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
|
Phase 3 | |
Recruiting |
NCT03817957 -
Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
|
Phase 3 | |
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Completed |
NCT03618914 -
Anemia and Inflammation
|
||
Completed |
NCT03940430 -
Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Completed |
NCT03237065 -
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
|
Phase 3 | |
Completed |
NCT05153278 -
IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
|